Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Green Tea Extract
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants PharmassêtX Orphan Drug Designation for Green Tea-Based IBD Treatment
Details : PSX-514 (epigallocatechin gallate) is a small molecule, amyloid precursor protein (APP) inhibitor indicated for the treatment of inflammatory bowel disease pouchitis.
Brand Name : PSX-514
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 10, 2024
Lead Product(s) : Green Tea Extract
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?